Evox Therapeutics

High-Level Overview

Evox Therapeutics is a privately held, Oxford-based biotechnology company founded in 2016, specializing in exosome-based drug delivery platforms to develop next-generation gene editing therapies for rare neurological and neurodegenerative diseases.[1][2][4] The company builds ExoEdit™, a proprietary technology that engineers exosomes—naturally occurring extracellular vesicles—to deliver CRISPR-based genome editing tools precisely to hard-to-reach tissues like the central nervous system (CNS), addressing root causes of conditions such as ALS, spinocerebellar ataxia type 2 (SCA2), Huntington’s disease, and other trinucleotide repeat disorders.[2][3][4] Evox serves patients with severe, genetically driven CNS diseases lacking effective treatments, solving key challenges in drug delivery for protein, antibody, and nucleic acid therapies by enabling targeted, safe, and potentially repeatable dosing with reduced long-term risks.[1][2]

Backed by blue-chip investors including Redmile, OrbiMed, GV, Invus, and Lilly, Evox advances a focused pipeline with its lead ATXN2-targeting CRISPR program on track for candidate nomination in mid-2025 and CTA-enabling studies in 2026, alongside an MSH3 program for Huntington’s.[3][4] This positions Evox for rapid scaling across monogenic and repeat-expansion indications, demonstrating strong growth momentum through strategic partnerships, expanded intellectual property, and recognition as a disruptor.[4][7][8]

Origin Story

Evox Therapeutics was co-founded in 2016 by Per Lundin, PhD, MBA, a serial entrepreneur with 15 years of experience in advanced therapies, including founding IsletOne Therapeutics (acquired in a PE-led trade sale) and involvement in five biotech ventures spanning cell therapies, exosomes, and non-viral delivery.[4][6] The idea emerged from harnessing exosomes' natural delivery capabilities, initially pioneered through Lundin's expertise and collaborations in extracellular vesicle research; key early contributions came from leaders like Dave Carter, PhD, Head of Research, who brought 20+ years of multidisciplinary work, including professorship at Oxford Brookes University, £1M+ in grants, and foundational publications on vesicles.[6]

Pivotal moments include building a comprehensive IP portfolio around DeliverEX™ for exosome engineering and evolving from broad exosome delivery to the specialized ExoEdit™ platform for genome editing.[1][2][7] By 2025, Evox gained traction with investor funding, a robust pipeline, and expansions like appointing world-class Scientific Advisory Board members in July 2025 to accelerate neurodegenerative programs.[3][4]

Core Differentiators

Evox stands out in biotech through its exosome-centric innovations tailored for CNS gene editing:

• ExoEdit™ Platform: Encapsulates CRISPR ribonucleoproteins in engineered exosomes for precise, natural delivery to CNS tissues, overcoming barriers of traditional vectors with high safety, tolerability, transient exposure, and potential for repeated dosing.[2][4]
• Proprietary Engineering (DeliverEX™): Enables molecular modifications, drug loading, and targeting to organs like the brain, supported by a substantial IP estate for scalability across modalities and diseases.[1][7]
• Pipeline Focus: Lead ATXN2 program for ALS/SCA2 (CTA 2026) and MSH3 for Huntington’s, with modular design for rapid expansion; three partnership-ready programs.[3][4]
• Leadership & Expertise: Co-founder/CEO Per Lundin’s track record in biotech exits; research head Dave Carter’s vesicle pioneering; expanded SAB with leaders like Professors Benatar, Tabrizi, and Urnov.[3][6]
• Investor & Ecosystem Strength: Backed by top VCs and pharma (e.g., Lilly), with values-driven culture emphasizing teamwork, respect, accountability, and excellence.[2][4]

Role in the Broader Tech Landscape

Evox rides the exploding gene editing wave, particularly CRISPR advancements, combined with the nascent exosome therapeutics trend, timing perfectly with rising demand for CNS-targeted treatments amid aging populations and unmet needs in neurodegenerative diseases like ALS and Huntington’s.[2][3][4] Market forces favoring Evox include regulatory momentum for gene therapies, limitations of AAV vectors (e.g., immunogenicity, redosability), and exosome advantages in safety and tissue penetration, positioning it to disrupt a $10B+ rare disease market.[1][2]

The company influences the ecosystem by pioneering exosome delivery standards, fostering partnerships, and validating the modality through milestones like NHP studies in Q3-Q4 2025, potentially accelerating industry adoption of natural vesicles over synthetic nanoparticles.[4][7]

Quick Take & Future Outlook

Evox is primed for inflection with its ATXN2 program hitting candidate nomination mid-2025 and CTA studies in 2026, alongside MSH3 progress and NHP data catalysts, fueling partnerships for its three pipeline assets.[4] Trends like multiplex editing, AI-optimized CRISPR, and exosome manufacturing scale will amplify ExoEdit™'s edge, evolving Evox from pipeline pioneer to CNS gene therapy leader—potentially via IPO, acquisition, or blockbuster approvals. This Oxford biotech's exosome revolution could redefine delivery for unreachable diseases, delivering on its mission to transform rare neurological outcomes.[2][3]